From: Dynamic serum biomarkers to predict the efficacy of PD-1 in patients with nasopharyngeal carcinoma
Characteristic cohort (n = 54) | Training cohort (n = 106) No. (%) | Validation No. (%) | p |
---|---|---|---|
Age, y | |||
 Median (range) | 47(24–73) | 43(19–78) | 0.9718 |
Sex | |||
 Female | 29 (27.36) | 18 (33.33) | 0.4660 |
 Male | 77 (72.64) | 36 (66.67) | |
Recurrence | |||
 Yes | 50 (47.17) | 23 (42.59) | 0.6180 |
 No | 56(52.83) | 31 (57.41) | |
ECOG | |||
 0 | 6 (5.66) | 9 (16.67) | 0.1930 |
 1 | 98 (92.45) | 45 (83.33) | |
 2 | 2 (1.89) | 0 (0.00) | |
Histological type | |||
 Poorly differentiated type | 3 (2.83) | 6 (11.11) | 0.0620 |
 Undifferentiated type | 103 (97.17) | 48 (88.89) | |
Clinical stage | |||
 II–III | 38 (35.85) | 19 (35.19) | 0.1430 |
 IVa | 21 (19.81) | 15 (27.78) | |
 IVb | 36(33.96) | 12 (22.22) | |
 IVc | 11 (10.38) | 8 (14.81) | |
Tumor stage | |||
 T0–2 | 24 (22.64) | 12 (22.22) | 0.9520 |
 T3–4 | 82 (77.36) | 42 (77.78) | |
Node stage | |||
 N0–1 | 47 (44.34) | 23 (42.59) | 0.8670 |
 N2–3 | 59 (55.66) | 31 (57.41) | |
Metastasis stage | |||
 M0 | 49 (46.23) | 28 (51.85) | 0.5090 |
 M1 | 57 (53.77) | 26(48.15) | |
Outcomes | |||
 PR | 24 (22.64) | 10 (18.52) | 0.0610 |
 SD | 68 (64.15) | 35 (64.81) | |
 PD | 14 (13.21) | 9 (16.67) | |
The PD1 drug | |||
 Camrelizumab | 16 (15.09) | 2 (3.70) | 0.2070 |
 Pembrolizumab | 3 (2.83) | 0 (0.00) | |
 Toripalimab | 72 (67.93) | 45 (83.33) | |
 Sintilimab | 15 (14.15) | 7 (12.97) |